Iodine Radioisotopes

"Iodine Radioisotopes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.

Descriptor ID	D007457
MeSH Number(s)	D01.268.380.400.500.496 D01.496.448.496 D01.496.749.474
Concept/Terms	Iodine Radioisotopes Iodine Radioisotopes Radioisotopes, Iodine

Below are MeSH descriptors whose meaning is more general than "Iodine Radioisotopes".

Chemicals and Drugs [D]
Inorganic Chemicals [D01]
Elements [D01.268]
Halogens [D01.268.380]
Iodine [D01.268.380.400]
Iodine Isotopes [D01.268.380.400.500]
Iodine Radioisotopes [D01.268.380.400.500.496]
Isotopes [D01.496]
Iodine Isotopes [D01.496.448]
Iodine Radioisotopes [D01.496.448.496]
Radioisotopes [D01.496.749]
Iodine Radioisotopes [D01.496.749.474]

Below are MeSH descriptors whose meaning is related to "Iodine Radioisotopes".

Below are MeSH descriptors whose meaning is more specific than "Iodine Radioisotopes".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Iodine Radioisotopes" by people in this website by year, and whether "Iodine Radioisotopes" was a major or minor topic of these publications.

Bar chart showing 110 publications over 25 distinct years, with a maximum of 11 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	0	1
1998	1	0	1
1999	1	0	1
2000	0	1	1
2001	1	0	1
2002	3	2	5
2003	3	5	8
2004	4	3	7
2005	5	2	7
2006	2	4	6
2007	1	2	3
2008	4	3	7
2009	0	4	4
2010	4	2	6
2011	5	6	11
2012	3	4	7
2013	1	2	3
2014	2	2	4
2015	0	6	6
2016	1	1	2
2017	1	3	4
2018	1	1	2
2019	1	3	4
2022	2	6	8
2024	1	0	1

Below are the most recent publications written about "Iodine Radioisotopes" by people in Profiles.

Ulloa-Padilla JP, Burkat CN, Morgenstern KE. Topical Application of Perchlorate: A Toxicity Study in Rats. Ophthalmic Plast Reconstr Surg. 2024 Mar-Apr 01; 40(2):198-200.

View in: PubMed
Brose MS, Robinson BG, Sherman SI, Jarzab B, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Sen S, Oliver JW, Banerjee K, Keam B, Capdevila J. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. Cancer. 2022 12 15; 128(24):4203-4212.

View in: PubMed
Brose MS, Smit JWA, Lin CC, Tori M, Bowles DW, Worden F, Shen DH, Huang SM, Tsai HJ, Alevizaki M, Peeters RP, Takahashi S, Rumyantsev P, Guan R, Babajanyan S, Ozgurdal K, Sugitani I, Pitoia F, Lamartina L. Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI). Thyroid. 2022 09; 32(9):1059-1068.

View in: PubMed
Lee IT, Chen W, Chen Q, Cole HA, Bischoff LA, Jessop AC, Sobel RK. Factors Associated With Radioactive Iodine Therapy-Acquired Nasolacrimal Duct Obstruction. Endocr Pract. 2022 Dec; 28(12):1210-1215.

View in: PubMed
Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, Campbell M, Dickson P, Duh QY, Ehya H, Goldner WS, Guo T, Haymart M, Holt S, Hunt JP, Iagaru A, Kandeel F, Lamonica DM, Mandel S, Markovina S, McIver B, Raeburn CD, Rezaee R, Ridge JA, Roth MY, Scheri RP, Shah JP, Sipos JA, Sippel R, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Yeh M, Cassara CJ, Darlow S. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 08; 20(8):925-951.

View in: PubMed
Brose MS, Pryma DA, Newbold KL. Mitogen-Activated Protein Kinase Inhibitor Selumetinib Fails to Increase the Complete Response Rate of Radioactive Iodine Alone in High-Risk Differentiated Thyroid Cancer: Lessons From the Phase III ASTRA Study. J Clin Oncol. 2022 06 10; 40(17):1847-1849.

View in: PubMed
Brose MS, Panaseykin Y, Konda B, de la Fouchardiere C, Hughes BGM, Gianoukakis AG, Joo Park Y, Romanov I, Krzyzanowska MK, Leboulleux S, Binder TA, Dutcus C, Xie R, Taylor MH. A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2022 02 17; 107(3):776-787.

View in: PubMed
Jafari ME, Paik DS. 131I Intake and Regulatory Compliance Following Administration of Capsular 131I Sodium Iodide for Treatment of Thyroid Disorders. Health Phys. 2022 02 01; 122(2):360-364.

View in: PubMed
Chirikova E, McConnell RJ, O'Kane P, Yauseyenka V, Little MP, Minenko V, Drozdovitch V, Veyalkin I, Hatch M, Chan JM, Huang CY, Mabuchi K, Cahoon EK, Rozhko A, Zablotska LB. Association between exposure to radioactive iodine after the Chernobyl accident and thyroid volume in Belarus 10-15?years later. Environ Health. 2022 01 07; 21(1):5.

View in: PubMed
Huillard O, Jouinot A, Tlemsani C, Brose MS, Arrondeau J, Meinhardt G, Fellous M, De Sanctis Y, Schlumberger M, Goldwasser F. Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial. Thyroid. 2019 12; 29(12):1820-1827.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement